
Sandoz
SDZNY | OTC
$101.09
+$0.08 (+0.08%)
At close: Nov 16, 2026, 3:58 PM ET
$100.70
-$0.39 (-0.39%)
Pre-market:
Nov 16, 2026, 11:29 AM ET
Sandoz Company Profile
Company profile explainedCompany Profile
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Key Executives
| Name | Position |
|---|---|
| Richard Saynor | Chief Executive Officer |
| Asaf Gal | Chief Technology Officer |
| Remco J. Steenbergen | Chief Financial Officer |
| Tripti Jha | Chief People Officer |
| Claire D'Abreu-Hayling | Chief Scientific Officer & President of Generics Development |
| Craig Marks | Head of Investor Relations |
| Glenn A. Gerecke | Chief Manufacturing & Supply Officer |
| Ingrid Sollerer | General Counsel & Chief Compliance Officer |
| Keren Haruvi | President of North America |
| Rebecca Guntern | Chief Commercial Officer |
| Simon Wolfgang Hartmut Goeller | Country President of Germany |
Sandoz

| Country | Switzerland |
| IPO Date | Oct 4, 2023 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 23,000 |
| CEO | Richard Saynor |
Contact Details
Centralbahnstrasse 4 Basel,
ZG 4051 Switzerland
Stock Details
| Ticker Symbol | SDZNY |
| Exchange | OTC |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 799926100 |
| ISIN Number | US7999261008 |
| SIC Code | n/a |
Recent News
- 13 days ago / zacks.comCOLL or SDZNY: Which Is the Better Value Stock Right Now?
- 20 days ago / seekingalpha.comSandoz Group AG (SDZNY) Q3 2026 Sales/Trading Call Transcript
- 20 days ago / wsj.comSandoz Shares Fall After Company Turns Cautious on Sales Guidance
- 20 days ago / reuters.comGeneric drugmaker Sandoz lowers sales outlook, lifts profit forecast
- 1 month ago / zacks.comNBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?
- 2 months ago / zacks.comGRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
- 2 months ago / prnewswire.commAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide
- 2 months ago / wsj.comSandoz Gets Canada Approval for Generic Version of Ozempic
- 2 months ago / seekingalpha.comSandoz Group AG (SDZNY) Analyst/Investor Day Transcript
- 2 months ago / zacks.comGRFS or SDZNY: Which Is the Better Value Stock Right Now?
Add to Watchlist
Select watchlists to add or remove SDZNY